title: Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.
authors.forename: Hannah
authors.initials: H
authors.lastname: Goyne
authors.forename: Pamela J B
authors.initials: PJ
authors.lastname: Stone
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Cannon
mesh_terms: D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating / Q000276:immunology / Q000494:pharmacology; D060890:B7-H1 Antigen / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017635:Clonal Anergy / Q000276:immunology; D003520:Cyclophosphamide / Q000276:immunology / Q000494:pharmacology; D003713:Dendritic Cells / Q000276:immunology; D004164:Diphosphonates / Q000494:pharmacology; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016233:Immunotherapy, Active / Q000379:methods*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology; D000077268:Pamidronate; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology*; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1 / Q000276:immunology; D000077211:Zoledronic Acid
chemical_list: D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D019496:Cancer Vaccines; D004164:Diphosphonates; D007093:Imidazoles; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; C475826:VTCN1 protein, human; D000077211:Zoledronic Acid; D003520:Cyclophosphamide; D000077268:Pamidronate